Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort
- PMID: 37787583
- DOI: 10.1002/jmv.29122
Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort
Abstract
Despite recent advances in prophylactic vaccination, SARS-CoV-2 infections continue to cause significant morbidity. A better understanding of immune response differences between vaccinated individuals with and without later SARS-CoV-2 breakthrough infection is urgently needed. CoV-ADAPT is a prospective long-term study comparing humoral (anti-spike-RBD-IgG, neutralization capacity, avidity) and cellular (spike-induced T-cell interferon-γ [IFN-γ] release) immune responses in individuals vaccinated against SARS-CoV-2 at four different time points (three before and one after third vaccination). In this cohort study, 62 fully vaccinated individuals presented with SARS-CoV-2 breakthrough infections vs 151 without infection 3-7 months following third vaccination. Breakthrough infections significantly increased anti-spike-RBD-IgG (p < 0.01), but not spike-directed T-cell IFN-γ release (TC) or antibody avidity. Despite comparable surrogate neutralization indices, the functional neutralization capacity against SARS-CoV-2-assessed via a tissue culture-based assay-was significantly higher following breakthrough vs no breakthrough infection. Anti-spike-RBD-IgG and antibody avidity decreased with age (p < 0.01) and females showed higher anti-spike-RBD-IgG (p < 0.01), and a tendency towards higher antibody avidity (p = 0.051). The association between humoral and cellular immune responses previously reported at various time points was lost in subjects after breakthrough infections (p = 0.807). Finally, a machine-learning approach based on our large immunological dataset (a total of 49 variables) from different time points was unable to predict breakthrough infections (area under the curve: 0.55). In conclusion, distinct differences in humoral vs cellular immune responses in fully vaccinated individuals with or without breakthrough infection could be demonstrated. Breakthrough infections predominantly drive the humoral response without boosting the cellular component. Breakthrough infections could not be predicted based on immunological data, which indicates a superior role of environmental factors (e.g., virus exposure) in individualized risk assessment.
Keywords: SARS-CoV-2; breakthrough infection; humoral and cellular immune responses; machine-learning; prediction; vaccination.
© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Similar articles
-
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.Allergy. 2022 Aug;77(8):2381-2392. doi: 10.1111/all.15247. Epub 2022 Feb 16. Allergy. 2022. PMID: 35124800 Free PMC article.
-
Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study.Front Immunol. 2023 Mar 2;14:1120556. doi: 10.3389/fimmu.2023.1120556. eCollection 2023. Front Immunol. 2023. PMID: 36936965 Free PMC article.
-
Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients-a longitudinal cohort study.Front Immunol. 2024 Sep 5;15:1432348. doi: 10.3389/fimmu.2024.1432348. eCollection 2024. Front Immunol. 2024. PMID: 39301017 Free PMC article.
-
Adaptive Immune Responses and Immunity to SARS-CoV-2.Front Immunol. 2022 May 4;13:848582. doi: 10.3389/fimmu.2022.848582. eCollection 2022. Front Immunol. 2022. PMID: 35603211 Free PMC article. Review.
-
Defending against SARS-CoV-2: The T cell perspective.Front Immunol. 2023 Jan 27;14:1107803. doi: 10.3389/fimmu.2023.1107803. eCollection 2023. Front Immunol. 2023. PMID: 36776863 Free PMC article. Review.
Cited by
-
Distinct features of humoral and cellular immunity against Omicron breakthrough infection among chronic liver disease patients: An experience from a follow-up cohort.Hum Vaccin Immunother. 2025 Dec;21(1):2544466. doi: 10.1080/21645515.2025.2544466. Epub 2025 Aug 15. Hum Vaccin Immunother. 2025. PMID: 40814801 Free PMC article.
-
Enhanced and long-lasting SARS-CoV-2 immune memory in individuals with common cold coronavirus cross-reactive T cell immunity.Front Immunol. 2025 Mar 21;16:1501704. doi: 10.3389/fimmu.2025.1501704. eCollection 2025. Front Immunol. 2025. PMID: 40191213 Free PMC article.
References
REFERENCES
-
- Holmes EC, Goldstein SA, Rasmussen AL, et al. The origins of SARS-CoV-2: a critical review. Cell. 2021;184(19):4848-4856. doi:10.1016/j.cell.2021.08.017
-
- Ortega N, Ribes M, Vidal M, et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat Commun. 2021;12(1):4740. doi:10.1038/s41467-021-24979-9
-
- Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3(1):e52-e61. doi:10.1016/S2666-5247(21)00267-6
-
- Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205-1211. doi:10.1038/s41591-021-01377-8
-
- Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83. doi:10.1056/NEJMoa2114114
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous